(COLO-B) Coloplast - Ratings and Ratios
Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0060448595
COLO-B: Ostomy Products, Wound Care, Continence Care, Urology Devices, Respiratory
Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, is a global leader in intimate healthcare products and services. The company operates across Denmark, the United States, the United Kingdom, France, and other international markets, focusing on improving the quality of life for individuals with chronic conditions. Its product portfolio spans multiple therapeutic areas, including ostomy care, continence care, wound care, and urology.
The companys Chronic Care segment offers solutions such as the SenSura Mio ostomy system, designed for individualized fit and discretion, and the Brava line of ostomy accessories. Its Continence Care segment provides products like SpeediCath catheters, designed for ease of use by both genders, and Peristeen Plus, a transanal irrigation system for bowel management. The Advanced Wound Care segment includes Biatain Silicone and Comfeel dressings, addressing various wound types, along with skin care products like cleansers and moisturizers.
Coloplasts Interventional Urology segment focuses on minimally invasive treatments for urological disorders, including urinary stones and prostate conditions. The company also offers voice and respiratory care solutions, such as the Provox voice prosthesis for laryngectomy patients and Tracoe tracheostomy care products. These solutions are complemented by a range of accessories, including adhesives and breathing tubes, to enhance patient comfort and functionality.
As of the latest data, Coloplast A/S is listed under the ticker symbol COLO-B on the Copenhagen exchange, classified under the Health Care Equipment industry. Its market capitalization stands at 157,847.06M DKK, reflecting its strong market presence. The companys trailing P/E ratio is 32.26, with a forward P/E of 26.81, indicating expectations of future earnings growth. The price-to-book ratio of 10.21 highlights its premium valuation relative to book value.
From a technical perspective, Coloplasts stock has shown recent price action around 702.40 DKK, with short-term moving averages (SMA 20: 708.79) slightly above the current price, while the SMA 50 (745.35) and SMA 200 (830.55) indicate a downtrend over the medium to long term. The Average True Range (ATR) of 17.63 suggests moderate volatility, providing insight into potential price fluctuations.
3-Month Forecast: Based on the intersection of
Additional Sources for COLO-B Stock
COLO-B Stock Overview
| Market Cap in USD | 24,077m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
COLO-B Stock Ratings
| Growth Rating | -42.9 |
| Fundamental | 40.2 |
| Dividend Rating | 49.7 |
| Rel. Strength | -14.1 |
| Analysts | - |
| Fair Price Momentum | 661.88 DKK |
| Fair Price DCF | 175.84 DKK |
COLO-B Dividends
| Dividend Yield 12m | 2.82% |
| Yield on Cost 5y | 2.27% |
| Annual Growth 5y | 4.10% |
| Payout Consistency | 99.9% |
COLO-B Growth Ratios
| Growth Correlation 3m | -94% |
| Growth Correlation 12m | -53% |
| Growth Correlation 5y | -49.9% |
| CAGR 5y | -5.66% |
| CAGR/Max DD 5y | -0.15 |
| Sharpe Ratio 12m | -0.60 |
| Alpha | -26.55 |
| Beta | 0.464 |
| Volatility | 24.18% |
| Current Volume | 139.4k |
| Average Volume 20d | 233.4k |
As of April 26, 2025, the stock is trading at DKK 725.20 with a total of 139,367 shares traded.
Over the past week, the price has changed by +2.69%, over one month by -0.49%, over three months by -12.08% and over the past year by -13.91%.
Partly, yes. Based on ValueRay Fundamental Analyses, Coloplast (CO:COLO-B) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 40.15 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COLO-B as of April 2025 is 661.88. This means that COLO-B is currently overvalued and has a potential downside of -8.73%.
Coloplast has no consensus analysts rating.
According to ValueRays Forecast Model, COLO-B Coloplast will be worth about 721.1 in April 2026. The stock is currently trading at 725.20. This means that the stock has a potential downside of -0.56%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 909.5 | 25.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 721.1 | -0.6% |